Thymosin Alpha-1 for Women: Immune Research, Long-COVID Claims, and What's Unproven
Thymosin alpha-1 has a real drug history outside the US and a busy second life in wellness marketing. Here is what has actually been studied, where the long-COVID and autoimmune claims come from, and where it stands with the FDA in 2026.
Thymosin alpha-1 (Tα1) is a small immune-signaling peptide originally isolated from the thymus. A synthetic version, thymalfasin, sold as Zadaxin, is approved in some countries for chronic hepatitis B and C. It is not FDA-approved in the US for any use. Claims that it treats long COVID, autoimmune disease or "weak immunity" go well beyond the evidence: COVID-19 studies are mostly retrospective and conflicting, and long-COVID claims rest on mechanism and anecdote rather than trial results. In the US, its compounding status has been unsettled for years, and as of FDA's May 2026 update it doesn't appear in any of the agency's 503A nomination categories.
What thymosin alpha-1 is
Tα1 is a 28-amino-acid peptide produced naturally in the thymus, the gland where T cells mature. In lab and clinical research it has been studied as an immune modulator: something that may nudge parts of the immune system, particularly T-cell and dendritic-cell responses, rather than simply suppressing or boosting everything. That framing is why it shows up in research on chronic viral infections, as a vaccine response enhancer, and in cancer care as an add-on.
Our thymosin alpha-1 profile covers the proposed mechanisms in more detail.
Approval status: outside the US vs inside
| Where | Status |
|---|---|
| Some countries outside the US | Thymalfasin (Zadaxin) is approved for hepatitis B and C, according to reviews cited in the Wikipedia summary of thymosin α1 (Garaci et al., 2007; Goldstein & Goldstein, 2009). |
| United States: FDA approval | Not approved for any indication. |
| United States: compounding | Had been placed in FDA's interim Category 2 (substances that may present significant safety risks); removed from Category 2 in September 2024 after the nominators withdrew its nomination, per Reed Smith. It was on the December 4, 2024 advisory committee agenda (A4PC). FDA's 503A categories document, updated May 14, 2026, doesn't list it in any category (FDA). |
| 2026 advisory committee reviews | Not among the seven peptides reviewed in July 2026 or the five scheduled for review before the end of February 2027, per the FDA Law Blog. |
What that means in practice: removal from Category 2 is not approval, and it does not put a substance on the list of ingredients that 503A pharmacies may use. The FDA Law Blog notes that peptides never listed in Category 1 could not legally be used in 503A compounding on that basis. If a clinic or pharmacy offers you compounded Tα1, it's fair to ask exactly what legal pathway they rely on. Our FDA peptide reclassification explainer covers the wider 2026 picture.
What the research shows
Hepatitis B and C
This is where thymalfasin earned its approvals abroad. Even here the evidence has limits: the regulatory nomination file submitted to FDA quotes a 2010 review noting that clinical trials "failed to conclusively support" Tα1's role when combined with interferon-based hepatitis C therapy. Hepatitis C treatment has since moved to direct-acting antivirals, which cure most infections.
COVID-19
Tα1 was used in hospitals in China early in the pandemic, which produced a set of observational studies:
- A retrospective review of 76 severe cases in Wuhan reported lower mortality in treated patients (11.11% vs 30.00%), as summarized in the monograph submitted to FDA's compounding docket.
- A larger retrospective study of 275 patients summarized in the same document found no benefit on T-cell recovery and longer viral clearance in the treated group.
- Two 2023 meta-analyses disagreed: one concluded Tα1 did not reduce mortality or length of hospitalization; a later one reported lower mortality but no change in length of stay (both cited in the Wikipedia summary).
Retrospective studies compare patients who happened to get a drug with those who didn't, so sicker or healthier patients can end up in one group. When studies like these conflict, the honest conclusion is "unproven."
Long COVID
Long-COVID marketing for Tα1 leans on two ideas: that persistent symptoms involve immune dysregulation, and that Tα1 modulates immunity. Both are reasonable research questions. But we did not find published randomized trial results showing Tα1 improves long-COVID symptoms. Claims you see online are based on mechanism, clinic experience and personal accounts. If a provider cites trial evidence, ask for the citation.
Autoimmune conditions
Autoimmune diseases are more common in women, which is one reason Tα1 is marketed to women. There's an obvious tension: in autoimmune disease the immune system is already attacking the body, and any immune-active substance could in theory help, do nothing, or make things worse. We found no good trial evidence for Tα1 as an autoimmune treatment. The FDA nomination monograph itself says not to use it in people being deliberately immunosuppressed, such as transplant recipients. See our guide to peptides and autoimmune conditions in women.
Myths vs evidence
| Claim | What the evidence supports |
|---|---|
| "It's an approved drug, so it's proven." | Approved in some countries for hepatitis B and C. That doesn't establish benefit for other uses, and it isn't approved in the US. |
| "It treats long COVID." | No published randomized trial results that we could find. |
| "It reduced COVID deaths." | Some retrospective studies and one meta-analysis suggest it; another meta-analysis found no mortality benefit. Unproven. |
| "It balances autoimmunity." | A hypothesis. No good trials in autoimmune disease. |
| "It's FDA-cleared now that it left Category 2." | No. Leaving Category 2 isn't approval, and it isn't on the 503A ingredients list. |
| "It has no side effects." | The nomination monograph lists transient liver enzyme rises, injection-site redness and pain, and rare rashes and joint pain. Safety in pregnancy and breastfeeding isn't established. |
Safety notes for women
- Pregnancy and breastfeeding: the nomination monograph advises caution; there is no established safety data.
- Autoimmune disease: discuss any immune-active product with the specialist managing your condition before using it.
- Transplant or immunosuppressive treatment: the monograph says not to use it.
- Liver: transient liver enzyme rises are listed; tell your clinician if you have liver disease.
- Product quality: anything sold as "research use only" is not made for human use and has no quality guarantee.
There is no approved US human dose, and research-use-only products are not sold for human use. Dosing for prescription peptides is set by the prescribing clinician.
If a clinic offers you thymosin alpha-1, ask
- What condition are you treating, and what evidence supports Tα1 for it specifically?
- Where will the product come from, and under what legal pathway is it being compounded or sourced?
- What monitoring will you do (for example, liver tests), and what would make us stop?
- How does this interact with my autoimmune condition, pregnancy plans or other medications?
- What would we expect to see, and by when, if it's working?
For researchers
Thymosin alpha-1 is also sold by research chemical suppliers for laboratory use. These products are not for human use, and nothing in this article is guidance on using them.
Research Suppliers (Not for Human Use)
Research use only: these suppliers sell peptides labeled for laboratory research, not for human use. Prescription peptides come from a licensed pharmacy with a prescription.
For more on immune and gut health topics, see our gut and immune health hub.
Sources
- Wikipedia. Thymosin α1 (summarizing Garaci et al., Ann N Y Acad Sci 2007; Goldstein & Goldstein, Expert Opin Biol Ther 2009; Shang et al., Int Immunopharmacol 2023; Soeroto et al., Inflammopharmacology 2023).
- Reed Smith. FDA removes certain peptide bulk drug substances from Category 2. Client Alert 2024-208.
- Alliance for Pharmacy Compounding. PCAC to discuss 503A bulks list substances. September 2024.
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. Updated May 14, 2026.
- Snow CD, Palmer KL. FDA's Pep(tide) Rally! What Compounders and Industry Need to Know. FDA Law Blog, April 21, 2026.
- Thymosin alpha-1 monograph submitted to FDA docket FDA-2024-N-4777 (nominator document, not an FDA assessment).